Vaxcyte, Inc.
PCVX
$54.58
-$1.63-2.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.85% | 41.15% | 49.20% | 64.24% | 62.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.13% | 73.22% | 47.87% | 57.94% | -17.55% |
| Operating Income | -69.13% | -73.22% | -47.87% | -57.94% | 17.55% |
| Income Before Tax | -79.83% | -106.38% | -29.42% | -48.09% | 24.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.83% | -106.38% | -29.42% | -48.09% | 24.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.83% | -106.38% | -29.42% | -48.09% | 24.18% |
| EBIT | -69.13% | -73.22% | -47.87% | -57.94% | 17.55% |
| EBITDA | -67.47% | -73.25% | -47.29% | -56.72% | 18.63% |
| EPS Basic | -78.20% | -87.44% | -11.56% | -21.90% | 42.50% |
| Normalized Basic EPS | -78.21% | -87.43% | -11.56% | -21.91% | 42.50% |
| EPS Diluted | -78.20% | -87.44% | -11.56% | -21.90% | 42.50% |
| Normalized Diluted EPS | -78.21% | -87.43% | -11.56% | -21.91% | 42.50% |
| Average Basic Shares Outstanding | 0.91% | 10.11% | 16.01% | 21.49% | 31.87% |
| Average Diluted Shares Outstanding | 0.91% | 10.11% | 16.01% | 21.49% | 31.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |